Literature DB >> 12835123

Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Mario van der Stelt1, Henrik H Hansen, Wouter B Veldhuis, Peter R Bär, Klaas Nicolay, Gerrit A Veldink, Johannes F G Vliegenthart, Harald S Hansen.   

Abstract

Endocannabinoids are thought to function as retrograde messengers, which modulate neurotransmitter release by activating presynaptic cannabinoid receptors. Anandamide and 2-arachidonoylglycerol (2-AG) are the two best studied endogenous lipids which can act as endocannabinoids. Together with the proteins responsible for their biosynthesis, inactivation and the cannabinoid receptors, these lipids constitute the endocannabinoid system. This system is proposed to be involved in various neurodegenerative diseases such as Parkinson's and Huntington's diseases as well as Multiple Sclerosis. It has been demonstrated that the endocannabinoid system can protect neurons against glutamate excitotoxicity and acute neuronal damage in both in vitro and in vivo models. In this paper we review the data concerning the involvement of the endocannabinoid system in neurodegenerative diseases in which neuronal cell death may be elicited by excitotoxicity. We focus on the biosynthesis of endocannabinoids and on their modes of action in animal models of these neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12835123     DOI: 10.1007/bf03033139

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  147 in total

1.  Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.

Authors:  M E Abood; G Rizvi; N Sallapudi; S D McAllister
Journal:  Neurosci Lett       Date:  2001-08-31       Impact factor: 3.046

2.  CB1 cannabinoid receptor induction in experimental stroke.

Authors:  K L Jin; X O Mao; P C Goldsmith; D A Greenberg
Journal:  Ann Neurol       Date:  2000-08       Impact factor: 10.422

3.  Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity.

Authors:  M Shen; S A Thayer
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

4.  Effects of delta-9-tetrahydrocannabinol on sensory evoked hippocampal activity in the rat: principal components analysis and sequential dependency.

Authors:  R E Hampson; T C Foster; S A Deadwyler
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

5.  Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.

Authors:  H H Hansen; P C Schmid; P Bittigau; I Lastres-Becker; F Berrendero; J Manzanares; C Ikonomidou; H H Schmid; J J Fernández-Ruiz; H S Hansen
Journal:  J Neurochem       Date:  2001-09       Impact factor: 5.372

Review 6.  Acute neuronal injury, excitotoxicity, and the endocannabinoid system.

Authors:  Mario van der Stelt; Wouter B Veldhuis; Mauro Maccarrone; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Vincenzo Di Marzo; Johannes F G Vliegenthart
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

7.  Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells.

Authors:  E V Berdyshev; P C Schmid; Z Dong; H H Schmid
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

8.  Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.

Authors:  A J Hampson; L M Bornheim; M Scanziani; C S Yost; A T Gray; B M Hansen; D J Leonoudakis; P E Bickler
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

9.  Identification of molecular species of glycerophospholipids and sphingomyelin using electrospray mass spectrometry.

Authors:  J L Kerwin; A R Tuininga; L H Ericsson
Journal:  J Lipid Res       Date:  1994-06       Impact factor: 5.922

10.  Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; J W Huffman; L Layward
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

View more
  5 in total

Review 1.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  Neurotoxins and neurotoxic species implicated in neurodegeneration.

Authors:  Juan Segura Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 3.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 4.  Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies.

Authors:  Allyn C Howlett; Somnath Mukhopadhyay; Derek C Norford
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-24       Impact factor: 4.147

5.  Transcriptome profiling of five brain regions in a 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Ying Lyu; Yiying Huang; Guiying Shi; Xuepei Lei; Keya Li; Ran Zhou; Lin Bai; Chuan Qin
Journal:  CNS Neurosci Ther       Date:  2021-08-04       Impact factor: 5.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.